

High producer selection from combinatorial libraries for recombinant protein and peptide production in *E. coli* and *V. natriegens*

1 Joel Eichmann^{1,2}, Markus Oberpaul³, Tobias Weidner¹, Doreen Gerlach³, Peter Czermak^{1,2,3*}

2 ¹ Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied
3 Sciences Mittelhessen, Giessen, Germany

4 ² Faculty of Biology and Chemistry, Justus-Liebig University of Giessen, Germany

5 ³ Branch for Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen,
6 Germany

7

8 * **Correspondence:**

9 Prof. Dr.-Ing. Peter Czermak

10 peter.czermak@lse.thm.de

11

12

13 **Supplementary material**

14 **1 Sequences**

15 **1.1 Synthetic RBS**

16 Supplemental Table 1: Sequences of synthetic RBS, designed using the RBS calculator (Salis et al.
17 2009; Espah Borujeni et al. 2014). Underlined sequences indicate BsaI-overhangs for Golden Gate
18 cloning.

| RBS | Secretion signal | RBS sequence 5' - 3' |
|------------|-------------------------|--|
| RBS1 | ssNapA | <u>GGAGAGTCTACAATATAATATAAGGAGGTCAGG</u> |
| RBS2 | ssTorA | <u>GGAGTTCACATACATAAACAATAGGGAGGACACAACAGG</u> |
| RBS3 | ssYahJ | <u>GGAGTAATAACCAAAACAAAAGAGGAGGTACCAACAGG</u> |
| RBS4 | ssYcdB | <u>GGAGTATAATAAACAGTAGATAAGGAGGTAATAACAGG</u> |
| RBS5 | ssDmsA | <u>GGAGCCTAGAGATTCTAAGATAAGGAGGTAATAACAGG</u> |

19

20

Supplemental Material

21 1.2 Secretion signals

22 Supplementals Table 2: Sequences of the secretion signals used for RBS design and periplasmic
23 translocation. Underlined sequences indicate BsaI-overhangs for Golden Gate cloning.

| Secretion signal | Peptide sequence | DNA sequence 5' – 3' |
|------------------|--|--|
| ssNapA | MKLSRRSFMKANAVAA AAAAAGLSVPGVARAV VGQ | <u>CAGGATGAAACTCAGTCGTCGTAGCTTTATGA</u> AAGCTAACGCCGTTGCGGCCGCTGCGGCGGCT GCCGGTCTGAGCGTGCCGGGCGTTGCCCGCGC CGTTGTTGGTCAG <u>AGTG</u> |
| ssTorA | MNNNDLFQASRRRFLA QLGGLTVAGMLGPSLLT PRRATAAQAATDA | <u>CAGGATGAACAATAACGATCTCTTTCAGGCAT</u> CACGTCGGCGTTTTCTGGCACAACCTCGGCGGC TTAACCGTCGCCGGGATGCTGGGGCCGTCATT GTTAACGCCGCGACGTGCGACTGCGGCGCAA GCGGCGACTGACGCT <u>AGTG</u> |
| ssYahJ | MKESNSRREFLSQSGKM VTAAALFGTSVPLAHAA VAGTL | <u>CAGGATGAAAGAAAGCAATAGCCGCCGTGAA</u> TTTCTGAGCCAGAGCGGTAAGATGGTCACCGC CGCCGCGCTGTTTGGTACCTCTGTGCCGCTCG CCCATGCGGCCGCTAGCTGGCACCCCTA <u>AGTG</u> |
| ssYcdB | MQYKDENGVNPSRRR LLKVIGALALAGSCPVA HAQKTQSA | <u>CAGGATGCAGTATAAAGATGAAAACGGCGTG</u> AATGAACCGTCACGCCGACGTTTACTGAAAGT GATAGGTGCACTGGCGCTGGCGGGAAGTTGTC CGGTCGCTCATGCACAAAAACGCAAAGTGC G <u>AGTG</u> |
| ssDmsA | MKTKIPDAVLAAEVSRR GLVKTTAIGGLAMASSA LTLFSAHA | <u>CAGGATGAAAACCAAATTCGGGATGCGGTG</u> CTGGCGGCGGAAGTGTCCCGTCGTGGCCTGGT GAAAACCACCGCGATTGGCGGCCTGGCGATG GCGTCCTCCGCGCTGACCCTGCCGTTTTCCCGT ATTGCGCATGCG <u>AGTG</u> |

24

25

26

27

28

29

Supplemental Material

30 1.3 Plasmid sequences from identified high producers (expression cassette only)

31 Bold characters indicate the T7-promoter, underlined characters indicate the RBS.

32 > High-producer 1 (IMPI)

33 ;T7::RBS3_ssDmsA-SUMO-GFP-Thr-IMPI_T7ter

34 **TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAAT**CCCCCTCTAGAAATAAC
35 TATTTACGGAGTAATAACCAAAACAAAAGAGGAGGTACCAACAGGATGAAAACCAAAA
36 TTCCGGATGCGGTGCTGGCGGCGGAAGTGTCCCGTCGTGGCCTGGTGAAAACCCGCG
37 ATTGGCGGCCTGGCGATGGCGTCCCTCCGCGCTGACCCTGCCGTTTTCCCGTATTGCGCAT
38 GCGAGTGAAGGTTCTTCTATGGCTAGCATGTTCGACTCAGAAGTCAATCAAGAAGCTAA
39 GCCAGAGGTCAAGCCAGAAGTCAAGCCTGAGACTCACATCAATTTAAAGGTGTCCGATG
40 GATCTTCAGAGATCTTCTTCAAGATCAAAAAGACCACTCCTTTAAGAAGGCTGATGGAA
41 GCGTTCGCTAAAAGACAGGGTAAGGAAATGGACTCCTTAAGATTCTTGTACGACGGTAT
42 TAGAATTCAAGCTGATCAGACCCCTGAAGATTTGGACATGGAGGATAACGATATTATTG
43 AGGCTCACAGAGAACAGATTGGTGGGATCGAGCTATCAGAGGAGAGCAAAGGCGAAGA
44 ACTGTTTACGGGCGTCGTGCCGATTCTGGTGGAACTGGATGGCGATGTCAATGGTCATA
45 AATTCAGCGTTAGCGGCGAAGGTGAAGGCGATGCGACCTATGGTAAACTGACGCTGAA
46 ATTTATTTGCACCACGGGTAAACTGCCGGTGCCGTGGCCGACCCTGGTTACCACGCTGAC
47 GTATGGTGTTCAGTGTTTCTCCCGCTACCCGGATCATATGAAACAACACGACTTTTTCAA
48 ATCAGCGATGCCGGAAGGTTATGTCCAGGAACGTACCATTTTCTTTAAAGATGACGGCA
49 ACTACAAAACCCGCGCCGAAGTCAAATTTGAAGGTGATACGCTGGTGAACCGTATTGAA
50 CTGAAAGGCATCGATTTCAAAGAAGATGGTAATATCCTGGGCCATAAACTGGAATATAA
51 CTACAATTCGCACAACGTTTACATTATGGCAGATAAACAGAAAAACGGTATCAAAGTCA
52 ACTTCAAAATCCGCCATAATATCGAAGATGGCTCTGTGCAACTGGCTGACCACTATCAG
53 CAAAACACCCCGATCGGTGATGGCCCGGTTCTGCTGCCGGACAATCATTACCTGAGCAC
54 CCAGTCTGCACTGAGTAAAGATCCGAACGAAAAACGTGACCACATGGTCCTGCTGGAAT
55 TTGTCACGGCGGCGGGTATCACGCTGGGTATGGATGAACTGTATAAAGAGCAAGGCGGC
56 GGCAGCCTGGTGCCGCGCGGAAGTATTGTGCTGATTTGTAACGGTGGTCACGAATACTA
57 CGAATGTGGCGGTGCTTGCGATAATGTCTGTGCTGATCTGCATATCCAAAACAAAACCA
58 ACTGCCCGATCATCAACATCCGTTGTAACGATAAATGCTACTGTGAAGATGGCTACGCG
59 CGCGACGTGAATGGTAAATGCATTCCGATCAAAGACTGTCCGAAAATCCGTAGCTAATG
60 GGTAATTGATTAATACTAGGCTGCTAAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGC
61 TGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGG
62 GTTTTTTG

63

64

65

66

67

68

69

Supplemental Material

70 > High-producer 2 (Lucimycin)
71 ;T7::RBS2_ssYahJ-His-Trx-GFP-Thr-Lucimycin_T7ter
72 **TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATCCCCTCTAGAAATAAC**
73 **TATTTACGGAGTTCCATACATAAACAATAGGGAGGACACAACAGGATGAAAGAAAGCA**
74 **ATAGCCGCCGTGAATTTCTGAGCCAGAGCGGTAAGATGGTCACCGCCGCCGCGCTGTTT**
75 **GGTACCTCTGTGCCGCTCGCCCATGCGGCGGTAGCTGGCACCCCTAAGTGAACATCATCA**
76 **CCATCACCACAGCGACAAAATTATCCACCTGACGGACGACAGTTTCGACACGGATGTTC**
77 **TGAAAGCCGATGGCGCGATTCTGGTTGACTTCTGGGCGGAATGGTGCGGCCCGTGTA**
78 **ATGATTGCACCGATCCTGGATGAAATTGCTGACGAATATCAGGGCAAACCTGACCGTGGC**
79 **GAAACTGAACATCGATCAAATCCGGGTACCGCCCCGAAATACGGCATTCTGTGGTATCC**
80 **CGACGCTGCTGCTGTTTAAAAACGGTGAAGTTGCGGCCACCAAAGTCGGTGCCCTGTCA**
81 **AAAGGTCAACTGAAAGAATTCCTGGACGCAAATCTGGCGCTATCAGAGGAGAGCAAAG**
82 **GCGAAGAAGTGTTCACGGGCGTTCGTGCCGATTCTGGTGGAACTGGATGGCGATGTCAAT**
83 **GGTCATAAATTCAGCGTTAGCGGCGAAGGTGAAGGCGATGCGACCTATGGTAAACTGAC**
84 **GCTGAAATTTATTTGCACCACGGGTAAACTGCCGGTGCCGTGGCCGACCCTGGTTACCA**
85 **CGCTGACGTATGGTGTTTCAGTGTTTCTCCCGCTACCCGGATCATATGAAACAACACGACT**
86 **TTTTCAAATCAGCGATGCCGGAAGGTTATGTCCAGGAACGTACCATTTTCTTTAAAGATG**
87 **ACGGCAACTACAAAACCCGCGCCGAAGTCAAATTTGAAGGTGATACGCTGGTGAACCGT**
88 **ATTGAACTGAAAGGCATCGATTTCAAAGAAGATGGTAATATCCTGGGCCATAAACTGGA**
89 **ATATAACTACAATTCGCACAACGTTTACATTATGGCAGATAAACAGAAAAACGGTATCA**
90 **AAGTCAACTTCAAATCCGCCATAATATCGAAGATGGCTCTGTGCAACTGGCTGACCAC**
91 **TATCAGCAAAACACCCCGATCGGTGATGGCCCGGTTCTGCTGCCGGACAATCATTACCT**
92 **GAGCACCCAGTCTGCACTGAGTAAAGATCCGAACGAAAAACGTGACCACATGGTCCTGC**
93 **TGGAATTTGTCACGGCGGCGGGTATCACGCTGGGTATGGATGAACTGTATAAAGAGCAA**
94 **GGCGGCGGCAGCCTGGTGCCGCGCGGAAGTCAGCACGGTTACGGCGCAGGTGGTCACG**
95 **GTCAGCAGGGTTACGGCTCGCAACACTCGTCGCACGCTCCGCAAGGCGGTCACGTCGTC**
96 **CGTGAACAGGGTTTTAGTGGCCACGTGCATGAACAGCAAGCGGGTCATCACCATGAAGC**
97 **CGGCCACCATGAACAGGCGGGTACCATGAACAAAGCGGCCAGCAAGTTCACGGCCAG**
98 **GGTCATGGCTATAAATCTCACGGTTACTAATGGGTAATTGATTAATACCTAGGCTGCTAA**
99 **ACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATA**
100 **ACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG**

101

102

103

104

105

106

107

108

109

Supplemental Material

110 > High-producer 3 (Uricase)

111 ;T7::RBS5_ssYahJ-His-Trx-GFP-Thr-Uricase_T7ter

112 **TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATCCCCTCTAGAAATAAC**
113 **TATTTACGGAGCCTAGAGATTCTAAGATAAGGAGGTAAATACAGGATGAAAGAAAGCA**
114 ATAGCCGCCGTGAATTTCTGAGCCAGAGCGGTAAGATGGTCACCGCCGCCGCGCTGTTT
115 GGTACCTCTGTGCCGCTCGCCCATGCGGCGGTAGCTGGCACCCCTAAGTGAACATCATCA
116 CCATCACCACAGCGACAAAATTATCCACCTGACGGACGACAGTTTCGACACGGATGTTC
117 TGAAAGCCGATGGCGCGATTCTGGTTGACTTCTGGGCGGAATGGTGCGGCCCGTGTAAA
118 ATGATTGCACCGATCCTGGATGAAATTGCTGACGAATATCAGGGCAAACCTGACCGTGGC
119 GAAACTGAACATCGATCAAAATCCGGGTACCGCCCCGAAATACGGCATTCTGTGGTATCC
120 CGACGCTGCTGCTGTTTAAAAACGGTGAAGTTGCGGCCACCAAAGTCGGTGCCCTGTCA
121 AAAGGTCAACTGAAAGAATTCCTGGACGCAAATCTGGCGCTATCAGAGGAGAGCAAAG
122 GCGAAGAAGTGTTCACGGGCGTTCGTGCCGATTCTGGTGGAACTGGATGGCGATGTCAAT
123 GGTCAATAATTCAGCGTTAGCGGCGAAGGTGAAGGCGATGCGACCTATGGTAAACTGAC
124 GCTGAAATTTATTTGCACCACGGGTAAACTGCCGGTGCCGTGGCCGACCCTGGTTACCA
125 CGCTGACGTATGGTGTTTCAGTGTTTCTCCCGCTACCCGGATCATATGAAACAACACGACT
126 TTTTCAAATCAGCGATGCCGGAAGGTTATGTCCAGGAACGTACCATTTTCTTTAAAGATG
127 ACGGCAACTACAAAACCCGCGCCGAAGTCAAATTTGAAGGTGATACGCTGGTGAACCGT
128 ATTGAACTGAAAGGCATCGATTTCAAAGAAGATGGTAATATCCTGGGCCATAAACTGGA
129 ATATAACTACAATTCGCACAACGTTTACATTATGGCAGATAAACAGAAAAACGGTATCA
130 AAGTCAACTTCAAATCCGCCATAATATCGAAGATGGCTCTGTGCAACTGGCTGACCAC
131 TATCAGCAAAACACCCCGATCGGTGATGGCCCGGTTCTGCTGCCGGACAATCATTACCT
132 GAGCACCCAGTCTGCACTGAGTAAAGATCCGAACGAAAAACGTGACCACATGGTCCTGC
133 TGGAATTTGTCACGGCGGGCGGGTATCACGCTGGGTATGGATGAACTGTATAAAGAGCAA
134 GGCGGCGGCAGCCTGGTGCCGCGCGGAAGTTTTGCTCGTCCCTTGCAGCGTCCTAGTGG
135 AAAGGGGACACCGCAGCAAGATCGCGAAGCCCTCATCAGTACACGATCTCCGATCATG
136 GGTATGGCAAAGACAGTGTTAAAGTCCTGCATGTTAAACGCGATGGCCAGTACACTCG
137 ATCAAAGAGTTTGAGGTAGGCACCCATCTGAAACTCTACTCCAAGAAAGACTACTTTCA
138 TGGCGACAATAGCGATATCGTGGCGACTGACAGCCAGAAAAATACCGTATATCTGCTCG
139 CGAAGAAATTTGGCATTGAGAATCCAGAGAAATTTGGGCTTATTCTTGCATCGCACTTCC
140 TGAACAAATATGCGCATGTGGAAGAAGTGCACATTCACGTGGAAGAATATCCCTGGCAA
141 CGGATTTGCCAGGATCAAGTTGGTGGTACAACCGGCGCATGTGGTGTGCTCCGAACTT
142 CAGTACGTTCAATAATCGCCAGAAACACAACCATGCCTTCATTTTACCCCTACGGAAGT
143 TCGCTATTGCGATGTGGTGTACGTCGTACTIONGAAACAGACCGTAATTAGCGGTA
144 TTCGTGGACTGCGGGTTCTGAAAACGACGCAAAGTAGCTTCGTGAACTTTGTGAACGAC
145 GAATTTTCGCTCTCTGCCGGATCAGTATGACCGCATTCTTCAACCATCGTCGATTGCTCTT
146 GGAATACTCACGCACCAATAATGTCAAATTCGTCAGGACTGGAATACGGTGAAGAAC
147 ATCATCATCAAGAAATTCGCGGGTGTCCGAATGTTGGCACTTCAAGCCCGTCGGTGCA
148 ACATACTCTGTATCTGACCGAGAAAGAAGTCTTAGATGCCTTGCCAGAAGTATCCGTGA
149 TTAGCATGACCATGCCGAACAAACACTACTTTAACTTTGACACAAAACCGTTTCAGTCG
150 GTTGTTCAGGTGAAAACAACGAGGTGTTTATCCCGGTCGATAAACCGCATGGCACCAT
151 TTACGCACAACCTGGCGCGCAAGGATCTGGCCTCTCACTTATAATGGGTAATTGATTAATA
152 CCTAGGCTGCTAAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCA
153 ATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG

154


155

Supplemental Material

156 **2 High Producers**


157 SDS-PAGE and / or Western Blot of top candidates shown in Table 1.

158 **2.1 IMPI**




159

160 Supplementary Figure 1: SDS-PAGE of ten top candidates for IMPI production in *E. coli*. Standard:
 161 Precision Plus Protein™ Unstained Protein Standard. S: soluble protein fraction; I: insoluble protein
 162 fraction.



163


164 Supplementary Figure 2: Western Blot of ten top candidates for IMPI production in *E. coli*.
 165 S: soluble protein fraction; I: insoluble protein fraction. Circles indicate the expected Bands
 166 according to sequencing of the expression plasmids. Primary antibody: Anti-GFP 3H9 (Chromotek),
 167 secondary antibody: Anti-Rat-HRP (Jackson Immuno).



168
169 Supplementary Figure 3: Colony PCR of selected clones for IMPI production in *V. natriegens*.
170 Controls: Combinatorial expression library FL1, genomic *V. natriegens* DNA, water. Sanger
171 sequencing of the PCR products revealed all clones to carry the same expression plasmid:
172 RBS2_ssYahJ-MBP-GFP-IMPI. Production resulted in insoluble product.

173

174 **2.2 Lucimycin**



175
176 Supplementary Figure 4: Colony PCR of selected clones for Lucimycin production in *V. natriegens*.
177 Controls: Combinatorial expression library FL5, genomic *V. natriegens* DNA, water. Sanger
178 sequencing of the PCR products revealed two expression plasmids: RBS2_ssDmsA-MBP-GFP-
179 Lucimycin (upper bands) and RBS2_YahJ-His₆-Trx-GFP-Lucimycin (lower bands).

180

181

182

183


184

Supplemental Material

200 3 Cropped images

201 3.1 Western Blots

202 Multiple cropped images of Western Blots are shown in the main article. Here, the full images are
203 shown.




204

205 Supplementary Figure 7: Full Western Blot of high-producer SUMO-GFP-IMPI (left). Fig. 5 in the
206 main article shows a cropped version of this image. Another high-producer not discussed in the main
207 article is shown on the right side of the blot. PP: Periplasmic fraction; CP: Cytoplasmic fraction; I:
208 Insoluble and membrane fraction. Standards left: Precision Plus Protein™ Western C Blotting
209 Standard (BioRad); standard right: Precision Plus Protein™ Unstained Protein Standard, Strep-
210 tagged (BioRad). Expected bands : left, SUMO-GFP-IMPI: 52,7 kDa; right, other high-producer:
211 77,2 kDa.

212

213

Supplemental Material



214

215 Supplementary Figure 8: Full Western Blot of high-producer ssYahJ-His-Trx-GFP fusion of
216 Lucimycin (left) and Uricase (right). The left site of this blot is partially shown in in Fig. 6 of the
217 main manuscript. PP: Periplasmic fraction; CP: Cytoplasmic fraction; I: Insoluble and membrane
218 fraction. Standards left: Precision Plus Protein™ Western C Blotting Standard (BioRad); standard
219 right: Precision Plus Protein™ Unstained Protein Standard, Strep-tagged (BioRad). Expected bands:
220 left, ssYahJ-His-Trx-GFP-Lucimycin: 53,2 kDa; right, ssYahJ-His-Trx-GFP-Uricase: 83,2 kDa.


221

222

223

224

225



226

227 Supplementary Figure 9: Full Western Blot of high-producer ssYahJ-His-Trx-GFP-Uricase at all
228 analysed time points. This blot is partially shown in in Fig. 7 of the main manuscript. PP: Periplasmic
229 fraction; CP: Cytoplasmic fraction; I: Insoluble and membrane fraction; S: full soluble protein after
230 BugBuster® extraction (diluted). Standards: Precision Plus Protein™ Unstained Protein Standard,
231 Strep-tagged (BioRad). Expected bands: ssYahJ-His-Trx-GFP-Uricase: 83,2 kDa.

232

233

234

235

236

237

238

239

240


241

242

243

244

245 **3.2 Agarose gels**



246

247 Supplementary Figure 10: BsaI-digestion of combinatorial expression library and single clones
 248 isolated from the library. The upper band represents the plasmid backbone and is expected at
 249 4302 bp. The lower bands represent the inserts. Due to the size difference of the fusion tags for
 250 purification, the inserts differ in size. All sizes are present in the library, while single clones carry
 251 only one of the possible inserts. Marker: 2-Log DNA Ladder (NEB). A cropped version of this image
 252 is found in the main article in Fig. 1 B.

253

254

255 **Literature**

256 Espah Borujeni, Amin; Channarasappa, Anirudh S.; Salis, Howard M. (2014): Translation rate is
 257 controlled by coupled trade-offs between site accessibility, selective RNA unfolding and sliding at
 258 upstream standby sites. In: *Nucleic acids research* 42 (4), S. 2646–2659. DOI: 10.1093/nar/gkt1139.

259 Salis, Howard M.; Mirsky, Ethan A.; Voigt, Christopher A. (2009): Automated design of synthetic
 260 ribosome binding sites to control protein expression. In: *Nature biotechnology* 27 (10), S. 946–950.
 261 DOI: 10.1038/nbt.1568.

262